Taiho v. Accord: Lonsurf® Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Taiho Pharmaceutical Co., Ltd. v. Accord Healthcare, Ltd. |
| Case Number | 1:19-cv-02321 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2019 – Apr 2024 4 years 4 months |
| Outcome | Dismissal Without Prejudice |
| Patents at Issue | |
| Accused Products | Lonsurf® (trifluridine and tipiracil hydrochloride) tablets |
Case Overview
The Parties
⚖️ Plaintiff
Japanese pharmaceutical company with a broad oncology pipeline. Its U.S. subsidiary, Taiho Oncology, Inc., markets Lonsurf® in the United States.
🛡️ Defendant
Generic pharmaceutical manufacturer with established U.S. market ambitions, part of Intas Pharmaceuticals, Ltd.
The Patents at Issue
This high-stakes oncology patent infringement dispute centered on Lonsurf® (trifluridine and tipiracil hydrochloride tablets), a branded oncology product. The four asserted U.S. patents protect the drug’s composition, formulations, and method claims. The inclusion of a reissue patent (USRE046284E) adds a layer of prosecutorial complexity.
- • US10456399B2 — Composition and method claims
- • USRE046284E — Reissue patent for specific formulations/methods
- • US9527833B2 — Method of use claims
- • US10457666B2 — Formulation and dosage claims
Developing a generic oncology drug?
Check if your formulation or method might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded with a stipulated dismissal without prejudice, filed on April 2, 2024. No damages were awarded, and no injunction was entered on the record. This outcome is a hallmark of a negotiated resolution, likely involving a licensed entry date for the generic, a royalty arrangement, or a market exclusivity agreement. The District of Delaware retains jurisdiction to enforce any disputes arising from this resolution.
Key Legal Issues
The case was a straightforward patent infringement action under the Hatch-Waxman framework. While no formal claim construction or merits finding entered the public record, the presence of USRE046284E (a reissue patent) among the asserted patents is notable. Reissue patents are vulnerable to **intervening rights defenses** under 35 U.S.C. § 252, which can limit damages for pre-reissue infringing acts. This vulnerability may have influenced the settlement posture, though specific details are confidential.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in oncology drug space
- Analyze competitors’ patenting strategies
- Understand Hatch-Waxman litigation trends
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Hatch-Waxman & oncology formulations
4 Patents Asserted
Covering Lonsurf®
Negotiated Resolution
Common in ANDA cases
✅ Key Takeaways
Multi-patent portfolios across composition, formulation, and method-of-use claims create significant leverage in ANDA litigation.
Explore multi-patent strategies →Reissue patents, while useful for broadening claims, should be thoroughly vetted for intervening rights vulnerabilities before assertion.
Analyze reissue patent risk →A multi-patent ANDA suit signals a high-cost litigation path; factor settlement economics and potential licensing arrangements early.
Evaluate settlement strategies →Carefully review jurisdiction-retention clauses in dismissal orders, as they can govern future enforcement of resolution agreements.
Understand dismissal terms →Frequently Asked Questions
Four U.S. patents: US10456399B2, USRE046284E, US9527833B2, and US10457666B2, covering compositions and methods related to Lonsurf® (trifluridine/tipiracil) tablets.
The parties stipulated to dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii), with each side bearing its own costs. The District of Delaware retained jurisdiction to enforce the parties’ resolution — strongly indicating a confidential settlement or licensing agreement.
It reinforces the value of multi-patent portfolio strategies in ANDA litigation and highlights the complexity reissue patents add to both assertion and defense strategies in pharmaceutical IP disputes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — U.S. Federal Courts Public Access to Court Electronic Records
- USPTO Patent Center — Search and retrieve patent data
- Cornell Legal Information Institute — 35 U.S.C. § 252 (Intervening Rights)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.